Company Analysis
Sign in

EyePoint, Inc. (EYPT)

Nasdaq: EYPT · Laboratory Analytical Instruments · Watertown, MA · filing with the SEC since 2005
Full chart Alerts Compare
Grade3.9
◀ Past 3.4● Present 3.5▶ Future 4.7
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

56 patents granted to the 7 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to EyePoint, Inc.’s names, not what it holds today.

Patents granted
56
52 utility, 4 design, 1976 to Dec 31, 2025
Granted in 2025
3
Against 9 in 2024 and 3 in 2023
Applications published
74
4 of them in 2025
Names they are printed under
7
a subsidiary, a former name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals13
Medical technology2
Organic fine chemistry2
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name7 counted
PSIMEDICA LIMITED a subsidiary
GB, as the owner printed on each patent
24 granted
20 published
EyePoint Pharmaceuticals, Inc. a former name
US, as the owner printed on each patent
22 granted
4 published
pSivida Corp a former name
US, as the owner printed on each patent
1 granted
22 published
EyePoint Pharmaceuticals, Inc. a former name
named as the applicant on its applications, in US
0 granted
15 published
ICON BIOSCIENCE, INC. a subsidiary
US, as the owner printed on each patent
9 granted
3 published
ICON BIOSCIENCE, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
8 published
pSiMedica Limited a subsidiary
named as the applicant on its applications, in GB
0 granted
2 published
Names not counted (1)
EyePoint, Inc.
Most of its patents print IL; this name counts in US. 1 granted and 1 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 16, 2025D1,106,444Ocular injectorEyePoint Pharmaceuticals, Inc.
Jun 17, 202512,329,859Bioerodible drug delivery devicesPharmaceuticalsEyePoint Pharmaceuticals, Inc.
Jan 7, 202512,187,715Small molecule activators of Tie-2Organic fine chemistryEyePoint Pharmaceuticals, Inc.
Dec 24, 202412,171,751Methods of treating intraocular pressure with activators of Tie-2PharmaceuticalsEyePoint Pharmaceuticals, Inc.
Nov 26, 202412,152,023Compositions, formulations and methods for treating ocular diseasesPharmaceuticalsEyePoint Pharmaceuticals, Inc.
Nov 19, 202412,145,986Method of treating an ocular condition by administering a humanized monoclonal antibodies that target VE-PTP (HPTP-Beta)PharmaceuticalsEyePoint Pharmaceuticals, Inc.
Sep 24, 2024D1,043,969Ocular injectorEyePoint Pharmaceuticals, Inc.
Aug 20, 202412,064,420Tie-2 activators targeting the Schlemm's canalPharmaceuticalsEyePoint Pharmaceuticals, Inc.
Jul 30, 2024D1,037,439Ocular injectorEyePoint Pharmaceuticals, Inc.
Jul 23, 202412,043,664Methods for treating vascular leak syndrome and cancerPharmaceuticalsEyePoint Pharmaceuticals, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jun 26, 20252025/0205152METHOD OF PREVENTING AGE-RELATED MACULAR DEGENERATION BY ADMINISTERING AN OCULAR DRUG DELIVERY INSERTPharmaceuticalsEyePoint Pharmaceuticals, Inc.
Jun 12, 20252025/0186398CONTINUOUS DOSING REGIMEN FOR TREATMENT OF A CONDITION OF THE EYEPharmaceuticalsEyePoint Pharmaceuticals, Inc.
Jun 12, 20252025/0186336METHOD OF TREATING WET AGE-RELATED MACULAR DEGENERATIONPharmaceuticalsEyePoint Pharmaceuticals, Inc.
Mar 13, 20252025/0082613TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANALPharmaceuticalsEyePoint Pharmaceuticals, Inc.
Jun 13, 20242024/0190857METHODS FOR MANUFACTURE OF SMALL MOLECULE ACTIVATORS OF TIE-2PharmaceuticalsEyePoint Pharmaceuticals, Inc.
May 30, 20242024/0174740MULTISPECIFIC ANTIBODIES THAT TARGET HPTP-BETA (VE-PTP) AND VEGFBiotechnologyEyePoint Pharmaceuticals, Inc. · patent 12,398,204 granted from it
Dec 14, 20232023/0398100METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2PharmaceuticalsEyePoint Pharmaceuticals, Inc. · patent 12,171,751 granted from it
Aug 24, 20232023/0265087SMALL MOLECULE ACTIVATORS OF TIE-2Organic fine chemistryEyePoint Pharmaceuticals, Inc. · patent 12,187,715 granted from it
May 4, 20232023/0139250FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOFPharmaceuticalsEyePoint Pharmaceuticals, Inc.
May 4, 20232023/0134885HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta)PharmaceuticalsEyePoint Pharmaceuticals, Inc. · patent 12,145,986 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 5 · Biotechnology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton EYPT · research, not advice